ID   TIE2_HUMAN              Reviewed;        1124 AA.
AC   Q02763; A8K6W0; B4DH20; B4DHD3; D3DRK5; E7EWI2; Q5TCU2; Q8IV34;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 2.
DT   10-MAY-2017, entry version 194.
DE   RecName: Full=Angiopoietin-1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Endothelial tyrosine kinase;
DE   AltName: Full=Tunica interna endothelial cell kinase;
DE   AltName: Full=Tyrosine kinase with Ig and EGF homology domains-2;
DE   AltName: Full=Tyrosine-protein kinase receptor TEK;
DE   AltName: Full=Tyrosine-protein kinase receptor TIE-2;
DE            Short=hTIE2;
DE   AltName: Full=p140 TEK;
DE   AltName: CD_antigen=CD202b;
DE   Flags: Precursor;
GN   Name=TEK; Synonyms=TIE2, VMCM, VMCM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, TISSUE
RP   SPECIFICITY, AND VARIANT PRO-346.
RC   TISSUE=Placenta;
RX   PubMed=8382358;
RA   Ziegler S.F., Bird T.A., Schneringer J.A., Schooley K.A., Baum P.R.;
RT   "Molecular cloning and characterization of a novel receptor protein
RT   tyrosine kinase from human placenta.";
RL   Oncogene 8:663-670(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND
RP   VARIANT PRO-346.
RC   TISSUE=Brain, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PRO-346.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-346.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 23-37.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [7]
RP   FUNCTION AS RECEPTOR FOR ANGPT1 AND ANGPT2, INTERACTION WITH ANGPT1
RP   AND ANGPT2, AND AUTOPHOSPHORYLATION.
RX   PubMed=9204896; DOI=10.1126/science.277.5322.55;
RA   Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J.,
RA   Radziejewski C., Compton D.L., McClain J., Aldrich T.H.,
RA   Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D.;
RT   "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo
RT   angiogenesis.";
RL   Science 277:55-60(1997).
RN   [8]
RP   SUBCELLULAR LOCATION, PROTEOLYTIC PROCESSING, AND TISSUE SPECIFICITY.
RX   PubMed=11806244; DOI=10.1023/A:1012226627813;
RA   Reusch P., Barleon B., Weindel K., Martiny-Baron G., Godde A.,
RA   Siemeister G., Marme D.;
RT   "Identification of a soluble form of the angiopoietin receptor TIE-2
RT   released from endothelial cells and present in human blood.";
RL   Angiogenesis 4:123-131(2001).
RN   [9]
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND PHOSPHORYLATION AT TYR-860; TYR-992 AND TYR-1108.
RX   PubMed=11513602; DOI=10.1021/bi010959e;
RA   Murray B.W., Padrique E.S., Pinko C., McTigue M.A.;
RT   "Mechanistic effects of autophosphorylation on receptor tyrosine
RT   kinase catalysis: enzymatic characterization of Tie2 and phospho-
RT   Tie2.";
RL   Biochemistry 40:10243-10253(2001).
RN   [10]
RP   FUNCTION IN REGULATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY;
RP   ENDOTHELIAL CELL MIGRATION AND REORGANIZATION OF THE ACTIN
RP   CYTOSKELETON.
RX   PubMed=12816861; DOI=10.1182/blood-2003-03-0670;
RA   Cascone I., Audero E., Giraudo E., Napione L., Maniero F.,
RA   Philips M.R., Collard J.G., Serini G., Bussolino F.;
RT   "Tie-2-dependent activation of RhoA and Rac1 participates in
RT   endothelial cell motility triggered by angiopoietin-1.";
RL   Blood 102:2482-2490(2003).
RN   [11]
RP   INTERACTION WITH TNIP2, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF LYS-855.
RX   PubMed=12609966; DOI=10.1161/01.RES.0000063422.38690.DC;
RA   Hughes D.P., Marron M.B., Brindle N.P.;
RT   "The antiinflammatory endothelial tyrosine kinase Tie2 interacts with
RT   a novel nuclear factor-kappaB inhibitor ABIN-2.";
RL   Circ. Res. 92:630-636(2003).
RN   [12]
RP   FUNCTION IN REGULATION OF ANGIOGENESIS; CELL SURVIVAL; CELL MIGRATION
RP   AND ACTIVATION OF AKT1, DOMAIN, AND INTERACTION WITH ANGPT1; ANGPT2
RP   AND ANGPT4.
RX   PubMed=15284220; DOI=10.1096/fj.03-1466com;
RA   Lee H.J., Cho C.H., Hwang S.J., Choi H.H., Kim K.T., Ahn S.Y.,
RA   Kim J.H., Oh J.L., Lee G.M., Koh G.Y.;
RT   "Biological characterization of angiopoietin-3 and angiopoietin-4.";
RL   FASEB J. 18:1200-1208(2004).
RN   [13]
RP   FUNCTION AS ANGPT1 RECEPTOR IN PHOSPHORYLATION OF SHC1 AND PIK3R1;
RP   REGULATION OF CELL MIGRATION AND ANGIOGENESIS, AUTOPHOSPHORYLATION,
RP   MUTAGENESIS OF TYR-1102, PHOSPHORYLATION AT TYR-1102, CATALYTIC
RP   ACTIVITY, AND INTERACTION WITH SHC1.
RX   PubMed=14665640; DOI=10.1074/jbc.M307456200;
RA   Audero E., Cascone I., Maniero F., Napione L., Arese M.,
RA   Lanfrancone L., Bussolino F.;
RT   "Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and
RT   regulates migration and sprouting but not survival of endothelial
RT   cells.";
RL   J. Biol. Chem. 279:13224-13233(2004).
RN   [14]
RP   INTERACTION WITH TIE1, SUBCELLULAR LOCATION, FUNCTION AS RECEPTOR FOR
RP   ANGPT1 IN PHOSPHORYLATION OF TIE1, AUTOPHOSPHORYLATION, CATALYTIC
RP   ACTIVITY, AND MUTAGENESIS OF LYS-855.
RX   PubMed=15851516; DOI=10.1083/jcb.200411105;
RA   Saharinen P., Kerkela K., Ekman N., Marron M., Brindle N., Lee G.M.,
RA   Augustin H., Koh G.Y., Alitalo K.;
RT   "Multiple angiopoietin recombinant proteins activate the Tie1 receptor
RT   tyrosine kinase and promote its interaction with Tie2.";
RL   J. Cell Biol. 169:239-243(2005).
RN   [15]
RP   FUNCTION AS ANGPT1 RECEPTOR IN ACTIVATION OF AKT1 OR MAPK1/ERK2 AND
RP   MAPK3/ERK1; REGULATION OF ENDOTHELIAL CELL MIGRATION AND CELL
RP   SPREADING, AND SUBCELLULAR LOCATION.
RX   PubMed=18425120; DOI=10.1038/ncb1714;
RA   Fukuhara S., Sako K., Minami T., Noda K., Kim H.Z., Kodama T.,
RA   Shibuya M., Takakura N., Koh G.Y., Mochizuki N.;
RT   "Differential function of Tie2 at cell-cell contacts and cell-
RT   substratum contacts regulated by angiopoietin-1.";
RL   Nat. Cell Biol. 10:513-526(2008).
RN   [16]
RP   FUNCTION AS ANGPT1 RECEPTOR IN ACTIVATION OF AKT1 OR MAPK1/ERK2 AND
RP   MAPK3/ERK1; REGULATION OF ENDOTHELIAL CELL MIGRATION AND REGULATION OF
RP   FOCAL ADHESION ASSEMBLY, INTERACTION WITH TIE1, AUTOPHOSPHORYLATION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=18425119; DOI=10.1038/ncb1715;
RA   Saharinen P., Eklund L., Miettinen J., Wirkkala R., Anisimov A.,
RA   Winderlich M., Nottebaum A., Vestweber D., Deutsch U., Koh G.Y.,
RA   Olsen B.R., Alitalo K.;
RT   "Angiopoietins assemble distinct Tie2 signalling complexes in
RT   endothelial cell-cell and cell-matrix contacts.";
RL   Nat. Cell Biol. 10:527-537(2008).
RN   [17]
RP   PHOSPHORYLATION, AND DEPHOSPHORYLATION BY PTPRB.
RX   PubMed=19116766; DOI=10.1007/s10456-008-9126-0;
RA   Yacyshyn O.K., Lai P.F.H., Forse K., Teichert-Kuliszewska K.,
RA   Jurasz P., Stewart D.J.;
RT   "Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in
RT   human endothelial cells.";
RL   Angiogenesis 12:25-33(2009).
RN   [18]
RP   INTERACTION WITH CBL, SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=19689429; DOI=10.1042/BJ20091010;
RA   Wehrle C., Van Slyke P., Dumont D.J.;
RT   "Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required
RT   for internalization and degradation.";
RL   Biochem. J. 423:375-380(2009).
RN   [19]
RP   INTERACTION WITH PTPRB.
RX   PubMed=19451274; DOI=10.1083/jcb.200811159;
RA   Winderlich M., Keller L., Cagna G., Broermann A., Kamenyeva O.,
RA   Kiefer F., Deutsch U., Nottebaum A.F., Vestweber D.;
RT   "VE-PTP controls blood vessel development by balancing Tie-2
RT   activity.";
RL   J. Cell Biol. 185:657-671(2009).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-596.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [21]
RP   FUNCTION AS RECEPTOR FOR ANGPT1 AND ANGPT2 IN ACTIVATION OF
RP   PHOSPHATIDYLINOSITOL 3-KINASE AND AKT1; STIMULATION OF ENDOTHELIAL
RP   CELL SURVIVAL AND MIGRATION, CATALYTIC ACTIVITY, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=19223473; DOI=10.1128/MCB.01472-08;
RA   Yuan H.T., Khankin E.V., Karumanchi S.A., Parikh S.M.;
RT   "Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in
RT   the endothelium.";
RL   Mol. Cell. Biol. 29:2011-2022(2009).
RN   [22]
RP   REVIEW ON FUNCTION; INTERACTION WITH EFFECTOR AND SCAFFOLDING
RP   PROTEINS, AND ROLE IN DISEASE.
RX   PubMed=18366015; DOI=10.14670/HH-23.773;
RA   Martin V., Liu D., Fueyo J., Gomez-Manzano C.;
RT   "Tie2: a journey from normal angiogenesis to cancer and beyond.";
RL   Histol. Histopathol. 23:773-780(2008).
RN   [23]
RP   REVIEW ON SUBCELLULAR LOCATION AND CONTEXT-SPECIFIC SIGNALING.
RX   PubMed=19293632; DOI=10.3858/emm.2009.41.3.016;
RA   Fukuhara S., Sako K., Noda K., Nagao K., Miura K., Mochizuki N.;
RT   "Tie2 is tied at the cell-cell contacts and to extracellular matrix by
RT   angiopoietin-1.";
RL   Exp. Mol. Med. 41:133-139(2009).
RN   [24]
RP   REVIEW.
RX   PubMed=19234476; DOI=10.1038/nrm2639;
RA   Augustin H.G., Koh G.Y., Thurston G., Alitalo K.;
RT   "Control of vascular morphogenesis and homeostasis through the
RT   angiopoietin-Tie system.";
RL   Nat. Rev. Mol. Cell Biol. 10:165-177(2009).
RN   [25]
RP   REVIEW.
RX   PubMed=20054809; DOI=10.14670/HH-25.387;
RA   Fukuhara S., Sako K., Noda K., Zhang J., Minami M., Mochizuki N.;
RT   "Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and
RT   angiogenesis.";
RL   Histol. Histopathol. 25:387-396(2010).
RN   [26]
RP   REVIEW ON SIGNALING, ENZYME REGULATION, AND ROLE IN DISEASE.
RX   PubMed=20651738; DOI=10.1038/nrc2894;
RA   Huang H., Bhat A., Woodnutt G., Lappe R.;
RT   "Targeting the ANGPT-TIE2 pathway in malignancy.";
RL   Nat. Rev. Cancer 10:575-585(2010).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 808-1124, ACTIVE SITE, ENZYME
RP   REGULATION, AND PREDICTION OF ATP-BINDING REGION.
RX   PubMed=11080633; DOI=10.1016/S0969-2126(00)00516-5;
RA   Shewchuk L.M., Hassell A.M., Ellis B., Holmes W.D., Davis R.,
RA   Horne E.L., Kadwell S.H., McKee D.D., Moore J.T.;
RT   "Structure of the Tie2 RTK domain: self-inhibition by the nucleotide
RT   binding loop, activation loop, and C-terminal tail.";
RL   Structure 8:1105-1113(2000).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 23-445 ALONE AND IN COMPLEX
RP   WITH ANGPT2, GLYCOSYLATION AT ASN-140, AND DISULFIDE BONDS.
RX   PubMed=16732286; DOI=10.1038/nsmb1101;
RA   Barton W.A., Tzvetkova-Robev D., Miranda E.P., Kolev M.V.,
RA   Rajashankar K.R., Himanen J.P., Nikolov D.B.;
RT   "Crystal structures of the Tie2 receptor ectodomain and the
RT   angiopoietin-2-Tie2 complex.";
RL   Nat. Struct. Mol. Biol. 13:524-532(2006).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 808-1124 IN COMPLEX WITH
RP   TRIAZINE DERIVATIVE, AND ENZYME REGULATION.
RX   PubMed=17350837; DOI=10.1016/j.bmcl.2007.02.067;
RA   Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S.,
RA   Caenepeel S., Cee V.J., Chaffee S.C., Emery M., Fretland J.,
RA   Gallant P., Gu Y., Johnson R.E., Kim J.L., Long A.M., Morrison M.,
RA   Olivieri P.R., Patel V.F., Polverino A., Rose P., Wang L., Zhao H.;
RT   "Synthesis, structural analysis, and SAR studies of triazine
RT   derivatives as potent, selective Tie-2 inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:2886-2889(2007).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 808-1124 IN COMPLEX WITH
RP   TRIAZINE DERIVATIVE, AND ENZYME REGULATION.
RX   PubMed=17253678; DOI=10.1021/jm061107l;
RA   Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S.,
RA   Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M.,
RA   Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R.,
RA   Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F.,
RA   Polverino A., Rose P., Tempest P., Wang L., Whittington D.A., Zhao H.;
RT   "Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-
RT   triazine Tie-2 kinase inhibitor.";
RL   J. Med. Chem. 50:611-626(2007).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 802-1124 IN COMPLEX WITH
RP   THIAZOLOPYRIMIDINE DERIVATIVE, AND ENZYME REGULATION.
RX   PubMed=19854647; DOI=10.1016/j.bmcl.2009.10.001;
RA   Luke R.W., Ballard P., Buttar D., Campbell L., Curwen J., Emery S.C.,
RA   Griffen A.M., Hassall L., Hayter B.R., Jones C.D., McCoull W.,
RA   Mellor M., Swain M.L., Tucker J.A.;
RT   "Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with
RT   activity against Tie-2 in vitro and in vivo.";
RL   Bioorg. Med. Chem. Lett. 19:6670-6674(2009).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 808-1124 IN COMPLEX WITH
RP   CEP11207.
RA   Fedorov A.A., Fedorov E.V., Pauletti D., Meyer S.L., Hudkins R.L.,
RA   Almo S.C.;
RT   "Crystal structure of cytoplasmic kinase domain of Tie2 complexed with
RT   inhibitor CEP11207.";
RL   Submitted (JAN-2010) to the PDB data bank.
RN   [33]
RP   VARIANT VMCM TRP-849.
RX   PubMed=8980225; DOI=10.1016/S0092-8674(00)81814-0;
RA   Vikkula M., Boon L.M., Carraway K.L. III, Calvert J.T., Diamonti A.J.,
RA   Goumnerov B., Pasyk K.A., Marchuk D.A., Warman M.L., Cantley L.C.,
RA   Mulliken J.B., Olse B.R.;
RT   "Vascular dysmorphogenesis caused by an activating mutation in the
RT   receptor tyrosine kinase TIE2.";
RL   Cell 87:1181-1190(1996).
RN   [34]
RP   VARIANTS VMCM TRP-849 AND SER-897.
RX   PubMed=10369874; DOI=10.1093/hmg/8.7.1279;
RA   Calvert J.T., Riney T.J., Kontos C.D., Cha E.H., Prieto V.G.,
RA   Shea C.R., Berg J.N., Nevin N.C., Simpson S.A., Pasyk K.A.,
RA   Speer M.C., Peters K.G., Marchuk D.A.;
RT   "Allelic and locus heterogeneity in inherited venous malformations.";
RL   Hum. Mol. Genet. 8:1279-1289(1999).
RN   [35]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-117.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-117; THR-148; VAL-226; ILE-486;
RP   LEU-600; PHE-634; ILE-676; THR-724; ALA-883 AND VAL-1124.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [37]
RP   INVOLVEMENT IN VMCM, INVOLVEMENT IN DISEASE, SUBCELLULAR LOCATION,
RP   CHARACTERIZATION OF VARIANTS VMCM TRP-849, VARIANTS HIS-897; PHE-897;
RP   SER-897; PHE-914; CYS-915; LEU-915 AND ILE-917, CHARACTERIZATION OF
RP   VARIANTS HIS-897; PHE-897; SER-897; PHE-914; CYS-915; LEU-915 AND
RP   ILE-917, AND PHOSPHORYLATION AT TYR-1102.
RX   PubMed=19079259; DOI=10.1038/ng.272;
RA   Limaye N., Wouters V., Uebelhoer M., Tuominen M., Wirkkala R.,
RA   Mulliken J.B., Eklund L., Boon L.M., Vikkula M.;
RT   "Somatic mutations in angiopoietin receptor gene TEK cause solitary
RT   and multiple sporadic venous malformations.";
RL   Nat. Genet. 41:118-124(2009).
RN   [38]
RP   VARIANTS VMCM TRP-849; CYS-897; HIS-915; CYS-918; LEU-919; SER-925 AND
RP   ASN-1100, AND CHARACTERIZATION OF VARIANTS VMCM TRP-849; SER-897;
RP   HIS-915; CYS-918; LEU-919; SER-925 AND ASN-1100.
RX   PubMed=19888299; DOI=10.1038/ejhg.2009.193;
RA   Wouters V., Limaye N., Uebelhoer M., Irrthum A., Boon L.M.,
RA   Mulliken J.B., Enjolras O., Baselga E., Berg J., Dompmartin A.,
RA   Ivarsson S.A., Kangesu L., Lacassie Y., Murphy J., Teebi A.S.,
RA   Penington A., Rieu P., Vikkula M.;
RT   "Hereditary cutaneomucosal venous malformations are caused by TIE2
RT   mutations with widely variable hyper-phosphorylating effects.";
RL   Eur. J. Hum. Genet. 18:414-420(2010).
RN   [39]
RP   INVOLVEMENT IN GLC3E, VARIANTS GLC3E 19-THR--ARG-210 DEL; TYR-233;
RP   ASN-294 AND CYS-611, CHARACTERIZATION OF VARIANTS GLC3E
RP   19-THR--ARG-210 DEL; TYR-233; ASN-294 AND CYS-611, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF CYS-224.
RX   PubMed=27270174; DOI=10.1172/JCI85830;
RA   Souma T., Tompson S.W., Thomson B.R., Siggs O.M., Kizhatil K.,
RA   Yamaguchi S., Feng L., Limviphuvadh V., Whisenhunt K.N.,
RA   Maurer-Stroh S., Yanovitch T.L., Kalaydjieva L., Azmanov D.N.,
RA   Finzi S., Mauri L., Javadiyan S., Souzeau E., Zhou T., Hewitt A.W.,
RA   Kloss B., Burdon K.P., Mackey D.A., Allen K.F., Ruddle J.B., Lim S.H.,
RA   Rozen S., Tran-Viet K.N., Liu X., John S., Wiggs J.L., Pasutto F.,
RA   Craig J.E., Jin J., Quaggin S.E., Young T.L.;
RT   "Angiopoietin receptor TEK mutations underlie primary congenital
RT   glaucoma with variable expressivity.";
RL   J. Clin. Invest. 126:2575-2587(2016).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis,
CC       endothelial cell survival, proliferation, migration, adhesion and
CC       cell spreading, reorganization of the actin cytoskeleton, but also
CC       maintenance of vascular quiescence. Has anti-inflammatory effects
CC       by preventing the leakage of proinflammatory plasma proteins and
CC       leukocytes from blood vessels. Required for normal angiogenesis
CC       and heart development during embryogenesis. Required for post-
CC       natal hematopoiesis. After birth, activates or inhibits
CC       angiogenesis, depending on the context. Inhibits angiogenesis and
CC       promotes vascular stability in quiescent vessels, where
CC       endothelial cells have tight contacts. In quiescent vessels,
CC       ANGPT1 oligomers recruit TEK to cell-cell contacts, forming
CC       complexes with TEK molecules from adjoining cells, and this leads
CC       to preferential activation of phosphatidylinositol 3-kinase and
CC       the AKT1 signaling cascades. In migrating endothelial cells that
CC       lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the
CC       extracellular matrix, leading to the formation of focal adhesion
CC       complexes, activation of PTK2/FAK and of the downstream kinases
CC       MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of
CC       sprouting angiogenesis. ANGPT1 signaling triggers receptor
CC       dimerization and autophosphorylation at specific tyrosine residues
CC       that then serve as binding sites for scaffold proteins and
CC       effectors. Signaling is modulated by ANGPT2 that has lower
CC       affinity for TEK, can promote TEK autophosphorylation in the
CC       absence of ANGPT1, but inhibits ANGPT1-mediated signaling by
CC       competing for the same binding site. Signaling is also modulated
CC       by formation of heterodimers with TIE1, and by proteolytic
CC       processing that gives rise to a soluble TEK extracellular domain.
CC       The soluble extracellular domain modulates signaling by
CC       functioning as decoy receptor for angiopoietins. TEK
CC       phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.
CC       {ECO:0000269|PubMed:12816861, ECO:0000269|PubMed:14665640,
CC       ECO:0000269|PubMed:15284220, ECO:0000269|PubMed:15851516,
CC       ECO:0000269|PubMed:18366015, ECO:0000269|PubMed:18425119,
CC       ECO:0000269|PubMed:18425120, ECO:0000269|PubMed:19223473,
CC       ECO:0000269|PubMed:20651738, ECO:0000269|PubMed:9204896}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11513602,
CC       ECO:0000269|PubMed:12609966, ECO:0000269|PubMed:14665640,
CC       ECO:0000269|PubMed:15851516, ECO:0000269|PubMed:19223473,
CC       ECO:0000269|PubMed:8382358}.
CC   -!- ENZYME REGULATION: Angiopoietin binding leads to receptor
CC       dimerization and activation by autophosphorylation at Tyr-992 on
CC       the kinase activation loop. Inhibited by staurosporine, K252a,
CC       PP2, damnacanthal, SB203580, CEP-11207, CEP-11981 and CE-245677.
CC       Inhibited by triazine, thienopyrimidine and thiazolopyrimidine
CC       derivatives. {ECO:0000269|PubMed:11080633,
CC       ECO:0000269|PubMed:11513602, ECO:0000269|PubMed:17253678,
CC       ECO:0000269|PubMed:17350837, ECO:0000269|PubMed:19854647,
CC       ECO:0000269|PubMed:20651738}.
CC   -!- SUBUNIT: Homodimer. Heterodimer with TIE1. Interacts with ANGPT1,
CC       ANGPT2 and ANGPT4. At cell-cell contacts in quiescent cells, forms
CC       a signaling complex composed of ANGPT1 plus TEK molecules from two
CC       adjoining cells. In the absence of endothelial cell-cell contacts,
CC       interaction with ANGPT1 mediates contacts with the extracellular
CC       matrix. Interacts with PTPRB; this promotes endothelial cell-cell
CC       adhesion. Interacts with DOK2, GRB2, GRB7, GRB14, PIK3R1 and
CC       PTPN11/SHP2. Colocalizes with DOK2 at contacts with the
CC       extracellular matrix in migrating cells. Interacts (tyrosine
CC       phosphorylated) with TNIP2. Interacts (tyrosine phosphorylated)
CC       with SHC1 (via SH2 domain). {ECO:0000269|PubMed:12609966,
CC       ECO:0000269|PubMed:14665640, ECO:0000269|PubMed:15284220,
CC       ECO:0000269|PubMed:15851516, ECO:0000269|PubMed:16732286,
CC       ECO:0000269|PubMed:17253678, ECO:0000269|PubMed:17350837,
CC       ECO:0000269|PubMed:18425119, ECO:0000269|PubMed:19451274,
CC       ECO:0000269|PubMed:19689429, ECO:0000269|PubMed:19854647,
CC       ECO:0000269|PubMed:9204896, ECO:0000269|Ref.32}.
CC   -!- INTERACTION:
CC       O15123:ANGPT2; NbExp=4; IntAct=EBI-2257090, EBI-2912111;
CC       Q05209:PTPN12; NbExp=2; IntAct=EBI-2257090, EBI-2266035;
CC       P23467:PTPRB; NbExp=3; IntAct=EBI-2257090, EBI-1265766;
CC       P08575:PTPRC; NbExp=3; IntAct=EBI-2257090, EBI-1341;
CC       Q12913:PTPRJ; NbExp=2; IntAct=EBI-2257090, EBI-2264500;
CC       Q15262:PTPRK; NbExp=2; IntAct=EBI-2257090, EBI-474052;
CC       Q16827:PTPRO; NbExp=2; IntAct=EBI-2257090, EBI-723739;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18425119,
CC       ECO:0000269|PubMed:18425120, ECO:0000269|PubMed:19079259,
CC       ECO:0000269|PubMed:27270174}; Single-pass type I membrane protein.
CC       Cell junction {ECO:0000269|PubMed:18425119,
CC       ECO:0000269|PubMed:18425120, ECO:0000269|PubMed:27270174}. Cell
CC       junction, focal adhesion {ECO:0000305|PubMed:19293632}. Cytoplasm,
CC       cytoskeleton. Secreted {ECO:0000269|PubMed:11806244}.
CC       Note=Recruited to cell-cell contacts in quiescent endothelial
CC       cells (PubMed:18425120, PubMed:18425119). Colocalizes with the
CC       actin cytoskeleton and at actin stress fibers during cell
CC       spreading. Recruited to the lower surface of migrating cells,
CC       especially the rear end of the cell. Proteolytic processing gives
CC       rise to a soluble extracellular domain that is secreted
CC       (PubMed:11806244). {ECO:0000269|PubMed:11806244,
CC       ECO:0000269|PubMed:18425119, ECO:0000269|PubMed:18425120}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q02763-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q02763-2; Sequence=VSP_042138;
CC       Name=3;
CC         IsoId=Q02763-3; Sequence=VSP_042137, VSP_042138, VSP_042139;
CC   -!- TISSUE SPECIFICITY: Detected in umbilical vein endothelial cells.
CC       Proteolytic processing gives rise to a soluble extracellular
CC       domain that is detected in blood plasma (at protein level).
CC       Predominantly expressed in endothelial cells and their
CC       progenitors, the angioblasts. Has been directly found in placenta
CC       and lung, with a lower level in umbilical vein endothelial cells,
CC       brain and kidney. {ECO:0000269|PubMed:11806244,
CC       ECO:0000269|PubMed:8382358}.
CC   -!- DOMAIN: The soluble extracellular domain is functionally active in
CC       angiopoietin binding and can modulate the activity of the
CC       membrane-bound form by competing for angiopoietins.
CC       {ECO:0000269|PubMed:15284220}.
CC   -!- PTM: Proteolytic processing leads to the shedding of the
CC       extracellular domain (soluble TIE-2 alias sTIE-2).
CC       {ECO:0000269|PubMed:11806244}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Autophosphorylation occurs in a sequential manner, where
CC       Tyr-992 in the kinase activation loop is phosphorylated first,
CC       followed by autophosphorylation at Tyr-1108 and at additional
CC       tyrosine residues. ANGPT1-induced phosphorylation is impaired
CC       during hypoxia, due to increased expression of ANGPT2.
CC       Phosphorylation is important for interaction with GRB14, PIK3R1
CC       and PTPN11. Phosphorylation at Tyr-1102 is important for
CC       interaction with SHC1, GRB2 and GRB7. Phosphorylation at Tyr-1108
CC       is important for interaction with DOK2 and for coupling to
CC       downstream signal transduction pathways in endothelial cells.
CC       Dephosphorylated by PTPRB. {ECO:0000269|PubMed:11513602,
CC       ECO:0000269|PubMed:14665640}.
CC   -!- PTM: Ubiquitinated. The phosphorylated receptor is ubiquitinated
CC       and internalized, leading to its degradation.
CC       {ECO:0000269|PubMed:19689429}.
CC   -!- DISEASE: Dominantly inherited venous malformations (VMCM)
CC       [MIM:600195]: An error of vascular morphogenesis characterized by
CC       dilated, serpiginous channels. {ECO:0000269|PubMed:10369874,
CC       ECO:0000269|PubMed:19079259, ECO:0000269|PubMed:19888299,
CC       ECO:0000269|PubMed:8980225}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Somatic mutations of TEK are associated with
CC       solitary and multiple sporadic venous malformations.
CC       {ECO:0000269|PubMed:19079259}.
CC   -!- DISEASE: Note=May play a role in a range of diseases with a
CC       vascular component, including neovascularization of tumors,
CC       psoriasis and inflammation.
CC   -!- DISEASE: Glaucoma 3, primary congenital, E (GLC3E) [MIM:617272]:
CC       An autosomal dominant form of primary congenital glaucoma (PCG).
CC       PCG is characterized by marked increase of intraocular pressure at
CC       birth or early childhood, large ocular globes (buphthalmos) and
CC       corneal edema. It results from developmental defects of the
CC       trabecular meshwork and anterior chamber angle of the eye that
CC       prevent adequate drainage of aqueous humor.
CC       {ECO:0000269|PubMed:27270174}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Tie subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TEKID42517ch9p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L06139; AAA61139.1; -; mRNA.
DR   EMBL; AK291775; BAF84464.1; -; mRNA.
DR   EMBL; AK294887; BAG57981.1; -; mRNA.
DR   EMBL; AK295043; BAG58094.1; -; mRNA.
DR   EMBL; AL133411; CAI16055.1; -; Genomic_DNA.
DR   EMBL; AL355432; CAI16055.1; JOINED; Genomic_DNA.
DR   EMBL; AL355433; CAI16055.1; JOINED; Genomic_DNA.
DR   EMBL; CH471071; EAW58571.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58572.1; -; Genomic_DNA.
DR   EMBL; BC035514; AAH35514.2; -; mRNA.
DR   CCDS; CCDS6519.1; -. [Q02763-1]
DR   CCDS; CCDS75825.1; -. [Q02763-2]
DR   CCDS; CCDS78389.1; -. [Q02763-3]
DR   PIR; I58388; I58388.
DR   RefSeq; NP_000450.2; NM_000459.4.
DR   RefSeq; NP_001277006.1; NM_001290077.1.
DR   RefSeq; NP_001277007.1; NM_001290078.1.
DR   UniGene; Hs.89640; -.
DR   PDB; 1FVR; X-ray; 2.20 A; A/B=808-1124.
DR   PDB; 2GY5; X-ray; 2.90 A; A=23-445.
DR   PDB; 2GY7; X-ray; 3.70 A; B=23-445.
DR   PDB; 2OO8; X-ray; 2.20 A; X=808-1124.
DR   PDB; 2OSC; X-ray; 2.80 A; A=808-1124.
DR   PDB; 2P4I; X-ray; 2.50 A; A/B=808-1124.
DR   PDB; 2WQB; X-ray; 2.95 A; A=802-1124.
DR   PDB; 3BEA; X-ray; 2.02 A; A=917-935.
DR   PDB; 3L8P; X-ray; 2.40 A; A=808-1124.
DR   PDB; 4K0V; X-ray; 4.51 A; A=23-542.
DR   PDB; 4X3J; X-ray; 2.50 A; A=802-1122.
DR   PDBsum; 1FVR; -.
DR   PDBsum; 2GY5; -.
DR   PDBsum; 2GY7; -.
DR   PDBsum; 2OO8; -.
DR   PDBsum; 2OSC; -.
DR   PDBsum; 2P4I; -.
DR   PDBsum; 2WQB; -.
DR   PDBsum; 3BEA; -.
DR   PDBsum; 3L8P; -.
DR   PDBsum; 4K0V; -.
DR   PDBsum; 4X3J; -.
DR   ProteinModelPortal; Q02763; -.
DR   SMR; Q02763; -.
DR   BioGrid; 112869; 10.
DR   DIP; DIP-6047N; -.
DR   IntAct; Q02763; 21.
DR   STRING; 9606.ENSP00000369375; -.
DR   BindingDB; Q02763; -.
DR   ChEMBL; CHEMBL4128; -.
DR   DrugBank; DB00415; Ampicillin.
DR   DrugBank; DB08221; N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB05294; Vandetanib.
DR   DrugBank; DB05153; XL184.
DR   GuidetoPHARMACOLOGY; 1842; -.
DR   iPTMnet; Q02763; -.
DR   PhosphoSitePlus; Q02763; -.
DR   UniCarbKB; Q02763; -.
DR   BioMuta; TEK; -.
DR   DMDM; 218511853; -.
DR   PaxDb; Q02763; -.
DR   PeptideAtlas; Q02763; -.
DR   PRIDE; Q02763; -.
DR   DNASU; 7010; -.
DR   Ensembl; ENST00000380036; ENSP00000369375; ENSG00000120156. [Q02763-1]
DR   Ensembl; ENST00000406359; ENSP00000383977; ENSG00000120156. [Q02763-2]
DR   Ensembl; ENST00000519097; ENSP00000430686; ENSG00000120156. [Q02763-3]
DR   GeneID; 7010; -.
DR   KEGG; hsa:7010; -.
DR   UCSC; uc003zqi.5; human. [Q02763-1]
DR   CTD; 7010; -.
DR   DisGeNET; 7010; -.
DR   GeneCards; TEK; -.
DR   GeneReviews; TEK; -.
DR   HGNC; HGNC:11724; TEK.
DR   HPA; CAB010359; -.
DR   HPA; HPA073265; -.
DR   MalaCards; TEK; -.
DR   MIM; 600195; phenotype.
DR   MIM; 600221; gene.
DR   MIM; 617272; phenotype.
DR   neXtProt; NX_Q02763; -.
DR   OpenTargets; ENSG00000120156; -.
DR   Orphanet; 2451; Mucocutaneous venous malformations.
DR   PharmGKB; PA36441; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00810000125384; -.
DR   HOGENOM; HOG000049232; -.
DR   HOVERGEN; HBG007316; -.
DR   InParanoid; Q02763; -.
DR   KO; K05121; -.
DR   OMA; CHEDTGE; -.
DR   OrthoDB; EOG091G00RL; -.
DR   PhylomeDB; Q02763; -.
DR   TreeFam; TF317568; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   SignaLink; Q02763; -.
DR   SIGNOR; Q02763; -.
DR   ChiTaRS; TEK; human.
DR   EvolutionaryTrace; Q02763; -.
DR   GeneWiki; TEK_tyrosine_kinase; -.
DR   GenomeRNAi; 7010; -.
DR   PRO; PR:Q02763; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000120156; -.
DR   CleanEx; HS_TEK; -.
DR   ExpressionAtlas; Q02763; baseline and differential.
DR   Genevisible; Q02763; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-KW.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IDA:HPA.
DR   GO; GO:0005902; C:microvillus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0060216; P:definitive hemopoiesis; TAS:UniProtKB.
DR   GO; GO:0001958; P:endochondral ossification; IEA:Ensembl.
DR   GO; GO:0001935; P:endothelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0072012; P:glomerulus vasculature development; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0060347; P:heart trabecula formation; ISS:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; TAS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; TAS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0051259; P:protein oligomerization; IDA:UniProtKB.
DR   GO; GO:2000351; P:regulation of endothelial cell apoptotic process; TAS:UniProtKB.
DR   GO; GO:0032878; P:regulation of establishment or maintenance of cell polarity; IMP:UniProtKB.
DR   GO; GO:0043114; P:regulation of vascular permeability; TAS:UniProtKB.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002040; P:sprouting angiogenesis; IMP:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0048014; P:Tie signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:UniProtKB.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 6.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR018941; Tyr_kin_Tie2_Ig-like_dom-1_N.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00041; fn3; 3.
DR   Pfam; PF10430; Ig_Tie2_1; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00181; EGF; 3.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF49265; SSF49265; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00022; EGF_1; 3.
DR   PROSITE; PS01186; EGF_2; 3.
DR   PROSITE; PS50026; EGF_3; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell junction; Cell membrane; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; EGF-like domain; Glaucoma; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Secreted; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        23   1124       Angiopoietin-1 receptor.
FT                                /FTId=PRO_0000024474.
FT   TOPO_DOM     23    748       Extracellular. {ECO:0000255}.
FT   TRANSMEM    749    769       Helical. {ECO:0000255}.
FT   TOPO_DOM    770   1124       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       44    123       Ig-like C2-type 1.
FT   DOMAIN      210    252       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      254    299       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      301    341       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      350    440       Ig-like C2-type 2.
FT   DOMAIN      447    541       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      545    636       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      641    735       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      824   1096       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     830    838       ATP. {ECO:0000305}.
FT   ACT_SITE    964    964       Proton acceptor.
FT                                {ECO:0000305|PubMed:11080633}.
FT   BINDING     855    855       ATP. {ECO:0000305}.
FT   MOD_RES     860    860       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11513602}.
FT   MOD_RES     992    992       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11513602}.
FT   MOD_RES    1102   1102       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14665640,
FT                                ECO:0000269|PubMed:27270174}.
FT   MOD_RES    1108   1108       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11513602}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16732286}.
FT   CARBOHYD    158    158       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    399    399       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    438    438       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    464    464       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    560    560       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    596    596       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    649    649       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    691    691       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     44    102       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    211    220       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    224    233       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    227    240       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    242    251       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    255    264       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    268    274       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    280    287       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    289    298       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    302    311       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    315    323       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    317    329       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    331    340       {ECO:0000269|PubMed:16732286}.
FT   DISULFID    370    424       {ECO:0000269|PubMed:16732286}.
FT   VAR_SEQ      18    121       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042137.
FT   VAR_SEQ     300    342       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042138.
FT   VAR_SEQ     788    788       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042139.
FT   VARIANT      19    210       Missing (in GLC3E; formation of protein
FT                                aggregates).
FT                                {ECO:0000269|PubMed:27270174}.
FT                                /FTId=VAR_078045.
FT   VARIANT     117    117       K -> N (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_035714.
FT   VARIANT     148    148       I -> T (in dbSNP:rs35969327).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041855.
FT   VARIANT     226    226       A -> V (in dbSNP:rs35814893).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041856.
FT   VARIANT     233    233       C -> Y (in GLC3E; enhanced proteasomal
FT                                degradation).
FT                                {ECO:0000269|PubMed:27270174}.
FT                                /FTId=VAR_078046.
FT   VARIANT     294    294       K -> N (in GLC3E; unknown pathological
FT                                significance; 10-fold decrease of Tyr-
FT                                1102 phosphorylation; no effect on
FT                                membrane location).
FT                                {ECO:0000269|PubMed:27270174}.
FT                                /FTId=VAR_078047.
FT   VARIANT     346    346       Q -> P (in dbSNP:rs682632).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8382358,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_048002.
FT   VARIANT     391    391       T -> I (in dbSNP:rs34032300).
FT                                /FTId=VAR_048003.
FT   VARIANT     486    486       V -> I (in dbSNP:rs1334811).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_024578.
FT   VARIANT     600    600       V -> L (in dbSNP:rs35030851).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041857.
FT   VARIANT     611    611       Y -> C (in GLC3E; reduced response to
FT                                ligand; loss of ligand-induced
FT                                phosphorylation; no effect on basal
FT                                membrane location).
FT                                {ECO:0000269|PubMed:27270174}.
FT                                /FTId=VAR_078048.
FT   VARIANT     634    634       L -> F (in dbSNP:rs35378598).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041858.
FT   VARIANT     676    676       V -> I (in dbSNP:rs56367117).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041859.
FT   VARIANT     724    724       A -> T (in dbSNP:rs4631561).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041860.
FT   VARIANT     849    849       R -> W (in VMCM; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation; no effect on location
FT                                at membrane; dbSNP:rs80338908).
FT                                {ECO:0000269|PubMed:10369874,
FT                                ECO:0000269|PubMed:19079259,
FT                                ECO:0000269|PubMed:19888299,
FT                                ECO:0000269|PubMed:8980225}.
FT                                /FTId=VAR_006352.
FT   VARIANT     883    883       P -> A (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041861.
FT   VARIANT     897    897       Y -> C (in VMCM; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation; dbSNP:rs80338909).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066606.
FT   VARIANT     897    897       Y -> F (found in a patient with multiple
FT                                sporadic venous malformations; increased
FT                                ligand-independent autophosphorylation;
FT                                the hyperphosphorylation increases when
FT                                associated with Leu-915).
FT                                {ECO:0000269|PubMed:19079259}.
FT                                /FTId=VAR_078049.
FT   VARIANT     897    897       Y -> H (found in a patient with solitary
FT                                sporadic venous malformations; increased
FT                                ligand-independent autophosphorylation).
FT                                {ECO:0000269|PubMed:19079259}.
FT                                /FTId=VAR_078050.
FT   VARIANT     897    897       Y -> S (in VMCM; also found in a patient
FT                                with solitary sporadic venous
FT                                malformations; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation; dbSNP:rs80338909).
FT                                {ECO:0000269|PubMed:10369874,
FT                                ECO:0000269|PubMed:19079259,
FT                                ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_008716.
FT   VARIANT     914    914       L -> F (found in patients with solitary
FT                                and multiple sporadic venous
FT                                malformations; increased ligand-
FT                                independent autophosphorylation; novel
FT                                location at endoplasmic reticulum and
FT                                Golgi apparatus; partially retained at
FT                                endoplasmic reticulum and Golgi
FT                                apparatus).
FT                                {ECO:0000269|PubMed:19079259}.
FT                                /FTId=VAR_078051.
FT   VARIANT     915    915       R -> C (found in a patient with solitary
FT                                sporadic venous malformations; increased
FT                                ligand-independent autophosphorylation).
FT                                {ECO:0000269|PubMed:19079259}.
FT                                /FTId=VAR_078052.
FT   VARIANT     915    915       R -> H (in VMCM; strongly increased
FT                                ligand-independent autophosphorylation
FT                                and kinase activation;
FT                                dbSNP:rs387906745).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066607.
FT   VARIANT     915    915       R -> L (found in a patient with multiple
FT                                sporadic venous malformations; increased
FT                                ligand-independent autophosphorylation;
FT                                the autophosphorylation increases when
FT                                associated with Phe-897).
FT                                {ECO:0000269|PubMed:19079259}.
FT                                /FTId=VAR_078053.
FT   VARIANT     917    917       S -> I (found in a patient with solitary
FT                                sporadic venous malformations; increased
FT                                ligand-independent autophosphorylation).
FT                                {ECO:0000269|PubMed:19079259}.
FT                                /FTId=VAR_078054.
FT   VARIANT     918    918       R -> C (in VMCM; strongly increased
FT                                ligand-independent autophosphorylation
FT                                and kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066608.
FT   VARIANT     919    919       V -> L (in VMCM; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066609.
FT   VARIANT     925    925       A -> S (in VMCM; increased ligand-
FT                                independent autophosphorylation and
FT                                kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066610.
FT   VARIANT    1100   1100       K -> N (in VMCM; strongly increased
FT                                ligand-independent autophosphorylation
FT                                and kinase activation).
FT                                {ECO:0000269|PubMed:19888299}.
FT                                /FTId=VAR_066611.
FT   VARIANT    1124   1124       A -> V (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041862.
FT   MUTAGEN     224    224       C->S: Reduces protein abundance.
FT                                {ECO:0000269|PubMed:27270174}.
FT   MUTAGEN     855    855       K->R: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:12609966,
FT                                ECO:0000269|PubMed:15851516}.
FT   MUTAGEN    1102   1102       Y->F: Abolishes interaction with SHC1.
FT                                {ECO:0000269|PubMed:14665640}.
FT   CONFLICT    536    536       F -> L (in Ref. 2; BAG58094).
FT                                {ECO:0000305}.
FT   CONFLICT    695    695       T -> I (in Ref. 1; AAA61139).
FT                                {ECO:0000305}.
FT   CONFLICT    939    940       QQ -> HH (in Ref. 5; AAH35514).
FT                                {ECO:0000305}.
FT   STRAND       26     29       {ECO:0000244|PDB:2GY5}.
FT   STRAND       33     35       {ECO:0000244|PDB:2GY5}.
FT   STRAND       40     46       {ECO:0000244|PDB:2GY5}.
FT   STRAND       56     59       {ECO:0000244|PDB:2GY5}.
FT   TURN         61     63       {ECO:0000244|PDB:2GY5}.
FT   STRAND       64     66       {ECO:0000244|PDB:2GY5}.
FT   STRAND       74     76       {ECO:0000244|PDB:2GY5}.
FT   STRAND       80     88       {ECO:0000244|PDB:2GY5}.
FT   STRAND       98    106       {ECO:0000244|PDB:2GY5}.
FT   STRAND      109    119       {ECO:0000244|PDB:2GY5}.
FT   STRAND      123    125       {ECO:0000244|PDB:2GY5}.
FT   STRAND      127    133       {ECO:0000244|PDB:2GY5}.
FT   STRAND      139    145       {ECO:0000244|PDB:2GY5}.
FT   STRAND      153    157       {ECO:0000244|PDB:2GY5}.
FT   STRAND      160    165       {ECO:0000244|PDB:2GY5}.
FT   HELIX       167    169       {ECO:0000244|PDB:2GY5}.
FT   STRAND      172    178       {ECO:0000244|PDB:2GY5}.
FT   HELIX       183    185       {ECO:0000244|PDB:2GY5}.
FT   STRAND      187    193       {ECO:0000244|PDB:2GY5}.
FT   HELIX       198    200       {ECO:0000244|PDB:2GY5}.
FT   STRAND      202    208       {ECO:0000244|PDB:2GY5}.
FT   STRAND      215    217       {ECO:0000244|PDB:2GY5}.
FT   TURN        235    237       {ECO:0000244|PDB:2GY5}.
FT   STRAND      246    248       {ECO:0000244|PDB:2GY5}.
FT   STRAND      259    261       {ECO:0000244|PDB:2GY5}.
FT   TURN        271    276       {ECO:0000244|PDB:2GY5}.
FT   STRAND      279    281       {ECO:0000244|PDB:2GY5}.
FT   TURN        282    285       {ECO:0000244|PDB:2GY5}.
FT   STRAND      286    288       {ECO:0000244|PDB:2GY5}.
FT   HELIX       296    298       {ECO:0000244|PDB:2GY5}.
FT   STRAND      322    324       {ECO:0000244|PDB:2GY5}.
FT   TURN        325    327       {ECO:0000244|PDB:2GY5}.
FT   STRAND      328    330       {ECO:0000244|PDB:2GY5}.
FT   STRAND      361    366       {ECO:0000244|PDB:2GY5}.
FT   STRAND      369    373       {ECO:0000244|PDB:2GY5}.
FT   HELIX       380    382       {ECO:0000244|PDB:2GY5}.
FT   STRAND      383    386       {ECO:0000244|PDB:2GY5}.
FT   STRAND      396    400       {ECO:0000244|PDB:2GY5}.
FT   STRAND      405    408       {ECO:0000244|PDB:2GY5}.
FT   STRAND      411    414       {ECO:0000244|PDB:2GY5}.
FT   HELIX       416    418       {ECO:0000244|PDB:2GY5}.
FT   STRAND      420    428       {ECO:0000244|PDB:2GY5}.
FT   STRAND      431    439       {ECO:0000244|PDB:2GY5}.
FT   STRAND      816    818       {ECO:0000244|PDB:1FVR}.
FT   HELIX       821    823       {ECO:0000244|PDB:1FVR}.
FT   STRAND      825    831       {ECO:0000244|PDB:1FVR}.
FT   HELIX       833    835       {ECO:0000244|PDB:1FVR}.
FT   STRAND      837    845       {ECO:0000244|PDB:1FVR}.
FT   STRAND      848    858       {ECO:0000244|PDB:1FVR}.
FT   HELIX       864    866       {ECO:0000244|PDB:2P4I}.
FT   HELIX       868    876       {ECO:0000244|PDB:1FVR}.
FT   STRAND      888    894       {ECO:0000244|PDB:1FVR}.
FT   STRAND      897    902       {ECO:0000244|PDB:1FVR}.
FT   HELIX       910    915       {ECO:0000244|PDB:1FVR}.
FT   HELIX       919    922       {ECO:0000244|PDB:1FVR}.
FT   HELIX       924    929       {ECO:0000244|PDB:1FVR}.
FT   STRAND      932    936       {ECO:0000244|PDB:2OO8}.
FT   HELIX       938    957       {ECO:0000244|PDB:1FVR}.
FT   HELIX       967    969       {ECO:0000244|PDB:1FVR}.
FT   STRAND      970    972       {ECO:0000244|PDB:1FVR}.
FT   HELIX       974    976       {ECO:0000244|PDB:1FVR}.
FT   STRAND      978    980       {ECO:0000244|PDB:1FVR}.
FT   STRAND      986    989       {ECO:0000244|PDB:1FVR}.
FT   TURN       1002   1004       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1007   1012       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1017   1032       {ECO:0000244|PDB:1FVR}.
FT   TURN       1038   1041       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1044   1050       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1051   1053       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1065   1074       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1079   1081       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1085   1097       {ECO:0000244|PDB:1FVR}.
FT   STRAND     1098   1100       {ECO:0000244|PDB:1FVR}.
FT   HELIX      1118   1120       {ECO:0000244|PDB:1FVR}.
SQ   SEQUENCE   1124 AA;  125830 MW;  E739DEC3E4FEB124 CRC64;
     MDSLASLVLC GVSLLLSGTV EGAMDLILIN SLPLVSDAET SLTCIASGWR PHEPITIGRD
     FEALMNQHQD PLEVTQDVTR EWAKKVVWKR EKASKINGAY FCEGRVRGEA IRIRTMKMRQ
     QASFLPATLT MTVDKGDNVN ISFKKVLIKE EDAVIYKNGS FIHSVPRHEV PDILEVHLPH
     AQPQDAGVYS ARYIGGNLFT SAFTRLIVRR CEAQKWGPEC NHLCTACMNN GVCHEDTGEC
     ICPPGFMGRT CEKACELHTF GRTCKERCSG QEGCKSYVFC LPDPYGCSCA TGWKGLQCNE
     ACHPGFYGPD CKLRCSCNNG EMCDRFQGCL CSPGWQGLQC EREGIQRMTP KIVDLPDHIE
     VNSGKFNPIC KASGWPLPTN EEMTLVKPDG TVLHPKDFNH TDHFSVAIFT IHRILPPDSG
     VWVCSVNTVA GMVEKPFNIS VKVLPKPLNA PNVIDTGHNF AVINISSEPY FGDGPIKSKK
     LLYKPVNHYE AWQHIQVTNE IVTLNYLEPR TEYELCVQLV RRGEGGEGHP GPVRRFTTAS
     IGLPPPRGLN LLPKSQTTLN LTWQPIFPSS EDDFYVEVER RSVQKSDQQN IKVPGNLTSV
     LLNNLHPREQ YVVRARVNTK AQGEWSEDLT AWTLSDILPP QPENIKISNI THSSAVISWT
     ILDGYSISSI TIRYKVQGKN EDQHVDVKIK NATITQYQLK GLEPETAYQV DIFAENNIGS
     SNPAFSHELV TLPESQAPAD LGGGKMLLIA ILGSAGMTCL TVLLAFLIIL QLKRANVQRR
     MAQAFQNVRE EPAVQFNSGT LALNRKVKNN PDPTIYPVLD WNDIKFQDVI GEGNFGQVLK
     ARIKKDGLRM DAAIKRMKEY ASKDDHRDFA GELEVLCKLG HHPNIINLLG ACEHRGYLYL
     AIEYAPHGNL LDFLRKSRVL ETDPAFAIAN STASTLSSQQ LLHFAADVAR GMDYLSQKQF
     IHRDLAARNI LVGENYVAKI ADFGLSRGQE VYVKKTMGRL PVRWMAIESL NYSVYTTNSD
     VWSYGVLLWE IVSLGGTPYC GMTCAELYEK LPQGYRLEKP LNCDDEVYDL MRQCWREKPY
     ERPSFAQILV SLNRMLEERK TYVNTTLYEK FTYAGIDCSA EEAA
//
